PureTech Health PLC PRTC Appoints Biotech Analyst & Senior Exec as CFO
05 Enero 2021 - 1:00AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
05 January 2021
5 January 2021
PureTech Health plc
PureTech Announces the Appointment of George Farmer, Ph.D., as
Chief Financial Officer
Experienced financial analyst and biotech executive added to
PureTech's strong leadership team
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, today announced that George
Farmer, Ph.D., has been appointed Chief Financial Officer.
"We are delighted to welcome George to the senior leadership
team as we are poised to build on the momentum of the past year,"
said Daphne Zohar, Founder and Chief Executive Officer of PureTech.
"This is an important moment for PureTech, as we recently initiated
three clinical trials based on programs from our Wholly Owned
Pipeline and expanded our presence with the NASDAQ Global Market
listing. We believe that George's depth of experience will be very
helpful as we share the PureTech story with a broader community of
investors."
As a key member of PureTech's senior leadership team, Dr. Farmer
will be responsible for all aspects of the Company's finances,
including capital markets strategy and execution, strategic and
financial planning, and financial reporting.
Dr. Farmer joins PureTech from BMO Capital Markets where he
completed a 15-year career as a senior biotechnology equity analyst
providing in-depth sector research for institutional investor
clients . Prior to this role, Dr. Farmer served as Chief Executive
Officer of Cortice Biosciences, a privately held biotechnology
company focused on the clinical development of therapies for brain
malignancies and neurodegenerative diseases. He also served as Vice
President of Corporate Development at Synta Pharmaceuticals, a
publicly traded company developing cancer therapeutics. Dr. Farmer
was a postdoctoral fellow at Sloan Kettering Cancer Center and
University of California San Francisco after receiving his Ph.D. in
Biological Sciences from Columbia University and a B.A. from
Dartmouth College.
"PureTech has built a leadership position in the science of the
brain-immune-gut axis, which has led to the discovery and
development of novel medicines. I am particularly intrigued by the
potential of LYT-100 for treating multiple fibrotic diseases and
LYT-200 as a potential new cancer immunotherapeutic. Just as
impressive is the track record of management, which has developed a
deep therapeutic pipeline both internally and through the Company's
Founded Entities," Dr. Farmer said. "I am very excited to become a
member of the PureTech team."
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
as of the date of PureTech's most recently filed Registration
Statement on Form 20-F, was comprised of 24 products and product
candidates, including two that have received FDA clearance and
European marketing authorization. All of the underlying programs
and platforms that resulted in this pipeline of product candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company's
unique insights into the biology of the brain, immune and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our product candidates, our expectations regarding the
appointment of our new Chief Financial Officer and those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
Investors EU media U.S. media
Allison Mead Talbot Ben Atwell, Rob Winder Adam Silverstein
+1 617 651 3156 +44 (0) 20 3727 1000 +1 917 697 9313
amt@puretechhealth.com ben.atwell@FTIconsulting.com adam@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAAFLELSFEAA
(END) Dow Jones Newswires
January 05, 2021 02:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024